• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Radiopharm Theranostics Limited

    6/3/26 8:00:04 AM ET
    $RADX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RADX alert in real time by email
    6-K 1 ea0293413-6k_radiopharm.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

    THE SECURITIES EXCHANGE ACT OF 1934

     

    For the Month of June 2026

     

    Commission File Number: 001-41621

     

    RADIOPHARM THERANOSTICS LIMITED

    (Name of Registrant)

     

    Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ☒       Form 40-F ☐

     

     

     

     

     

    RADIOPHARM THERANOSTICS LIMITED

     

    EXPLANATORY NOTE

     

    Radiopharm Theranostics Limited (the “Company”) published one announcement (the “Public Notice”) to the Australian Securities Exchange on June 3, 2026 titled:

     

    “Notification of cessation of securities - RAD”

     

    A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.

     

    This report on Form 6-K (including any exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934 and shall not be incorporated by reference into any registration statement or prospectus under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such registration statement or prospectus.

     

    1

     

     

    EXHIBITS

     

    Exhibit
    Number
      Description
    99.1   Notification of cessation of securities - RAD

     

    2

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      RADIOPHARM THERANOSTICS LIMITED
         
    Date: June 3, 2026 By: /s/ Nathan Jong
        Nathan Jong
        Company Secretary

     

    3

     

    Get the next $RADX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RADX

    DatePrice TargetRatingAnalyst
    3/12/2025$15.00Buy
    B. Riley Securities
    More analyst ratings

    $RADX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on Radiance Medical with a new price target

    B. Riley Securities initiated coverage of Radiance Medical with a rating of Buy and set a new price target of $15.00

    3/12/25 7:30:55 AM ET
    $RADX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RADX
    SEC Filings

    View All

    SEC Form 6-K filed by Radiopharm Theranostics Limited

    6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)

    6/3/26 8:00:04 AM ET
    $RADX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Radiopharm Theranostics Limited

    6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)

    4/23/26 8:00:38 AM ET
    $RADX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Radiopharm Theranostics Limited

    6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)

    4/20/26 8:00:31 AM ET
    $RADX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RADX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Voliotis Dimitris

    3 - Radiopharm Theranostics Ltd (0001949257) (Issuer)

    5/6/26 9:08:41 PM ET
    $RADX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Hopper Paul claimed ownership of 147,721,428 units of Ordinary Shares (SEC Form 3)

    3 - Radiopharm Theranostics Ltd (0001949257) (Issuer)

    5/6/26 6:08:16 AM ET
    $RADX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Laurita Aaron James claimed ownership of 26,357 units of Ordinary Shares (SEC Form 3)

    3 - Radiopharm Theranostics Ltd (0001949257) (Issuer)

    4/30/26 9:51:42 PM ET
    $RADX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RADX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology

    Issued on behalf of GT Biopharma, Inc. From bispecific ADCs at IDEAYA to a GSK partnership at Summit, B7-H3 has become one of the most actively pursued antigens in solid tumor oncology — and a new natural killer cell engager just entered the clinic SAN FRANCISCO, May 14, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary — For more than two decades, B7-H3 sat on the shortlist of theoretically perfect cancer drug targets that nobody could quite figure out how to hit. The protein is broadly overexpressed across some of the most common — and most lethal — solid tumors, including prostate, lung, breast, ovarian, head and neck, and pancreatic cancers. It is largely absent from healthy ti

    5/14/26 9:15:00 AM ET
    $GTBP
    $IDYA
    $RADX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing

    NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Depositary Receipts Virtual Investor Conference ("dbVIC") held April 28th are now available for online viewing. VIEW PRESENTATIONS HERE The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company's resource section. April 28th Company Presentations Lotus Technology Inc. (NASDAQ:LOT)Viomi Technology Co., Ltd (NASDAQ:VIOT)Belite Bio, Inc (NASDAQ:BLTE)First Pacific Company Ltd ((HKEX: 142, OTC:FPAFY)HUTCHMED (China) Limited (AIM:

    4/29/26 8:35:00 AM ET
    $BLTE
    $HCM
    $LOT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Auto Manufacturing
    Industrials

    International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on April 28, 2026

    NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference ("dbVIC") on Tuesday, April 28, 2026 featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the United States. Representatives from participating companies based in Australia, China, Hong Kong, Portugal, Netherlands, Cayman Islands and France, will respond to questions during formal presentations. The conference is targeted to all categories of investors and analysts interested in international companies. There is no fee for participants to log in, attend live presentations and/or ask qu

    4/23/26 8:35:00 AM ET
    $BLTE
    $HCM
    $LOT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Auto Manufacturing
    Industrials

    $RADX
    Leadership Updates

    Live Leadership Updates

    View All

    Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

    SYDNEY, July 22, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce the appointment of Dr Oliver Sartor, MD to the Company's Scientific Advisory Board (SAB). Dr Sartor is an internationally recognised medical oncologist and scientist specialising in prostate cancer and radiopharmaceutical therapies. He currently serves as Director of Radiopharmaceutical Clinical Trials and Chair of the Genitourinary Cancer Disease Group at the world-renowned Mayo Clinic, in Rochester, Minnesota. He w

    7/22/25 8:00:00 AM ET
    $RADX
    Biotechnology: Pharmaceutical Preparations
    Health Care